



Shivalik Rasayan Limited



CREATING
POSSIBILITIES.

SHAPING
FUTURE.

44th ANNUAL REPORT
2021-22

ACROSS THE PAGES



CORPORATE OVERVIEW

2-9

About the Company	2
Enhancing Possibilities, Shaping Tomorrow	4
Financial performance	5
Chairman's Message	6
Board of Directors	8
Corporate Information	9



STATUTORY REPORTS

10-68

Notice	10
Board's Report	18
Management Discussion & Analysis	27
Corporate Governance Report	30
Business Responsibility & Sustainability Report	44



FINANCIAL STATEMENTS

69-140

Standalone	69
Consolidated	103

INVESTOR INFORMATION

Market Cap	₹ 1,351.63 crores (BSE)
	₹ 1,345.61 crores (NSE)
CIN	L24237UR1979PLC005041
BSE Code	539148
NSE Symbol	SHIVALIK
Dividend Declared	10%
AGM Date	September 29, 2022
AGM Mode	Physical

Disclaimer: This document contains statements about expected future events and financials of Shivalik Rasayan Limited, which are forward-looking. By their nature, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is a significant risk that the assumptions, predictions, and other forward-looking statements may not prove to be accurate. Readers are cautioned not to place undue reliance on forward-looking statements as several factors could cause assumptions, actual future results and events to differ materially from those expressed in the forward-looking statements. Accordingly, this document is subject to the disclaimer and qualified in its entirety by the assumptions, qualifications and risk factors referred to in the Management Discussion and Analysis section of this Annual Report.





CREATING **POSSIBILITIES.** SHAPING **FUTURE.**

Ever since we started this journey, we have been consistently working to create new doors of possibilities. Our endeavours are always focused on progressing with excellence and living up to our customers' expectations, while also creating value for stakeholders. We have worked hard to gain expertise and experience while driving cost optimisation through our timely, effective and quality deliverables. Together, these efforts would help us become one of the leading market players in API's manufacturing domain.

As a well-known environment-friendly producer of plant-protection agrochemicals, we actively participate and contribute to society's betterment through our sustainability-led efforts. By leveraging our robust R&D capabilities, we are poised to tap the potential opportunities in plant protection agrochemicals. Our skilled employees and team, alongside our extensive global network, help nurture our capabilities and preparedness. Thereby, enabling us to Create Possibilities, while Shaping Future.



SHIVALIK RASAYAN: AT A GLANCE

Over four decades of industry leadership, as a manufacturer of agrochemicals and APIs in India.

Established in 1981, Today, Shivalik Rasayan Limited (the Company) manufactures quality agrochemical and APIs in India. With a well-established presence in India and globally, the Company is the largest producer of international quality Dimethoate Technical and the second-largest producer of Malathion Technical in India. Shivalik Rasayan is also amongst the most reputed and reliable manufacturers with world-class R&D facilities, supporting the Company in catering to its products' global demand.

The Company's facility at Dehradun, Uttarakhand, and a specialised research and development centre at Bhiwadi, drive its futuristic and strategic endeavours. In line with its vision, Shivalik Rasayan has setup WHO-GMP-approved facility at Dahej, Gujarat. The Company manufactures quality APIs at this facility and recently submitted its 1st US Drug Master file for Bortezomib through USFDA, taking a step ahead in diversifying its world-class product portfolio.



MISSION

To be a fast-growing and leading Generic APIs and advanced key pharma intermediates company enabling affordable healthcare worldwide by redefining our healthcare products innovatively with leadership in quality and costs.

3,500 MT

PROPOSED PRODUCTION CAPACITY

50,000 m²

TOTAL PLANT AREA

VALUES

Impact

Our core values reside in our commitment to customers in meeting timelines, quality and cost.

Knowledge

Our values exist owing to our talented pool of scientists and associated teams for their consistent and rigorous efforts for innovation and achieving affordability for our products.

Care

We value our team, teamwork, high level of integrity, mutual trust and respect among each other.



SHIVALIK'S FACILITIES

- Research and Development centre at Bhiwadi, Rajasthan, recognised by the Department of Scientific and Industrial Research (DSIR), Government of India
- API facility at Dahej II- a USFDA/EU - compliant facility
- Dehradun facility is equipped with the latest equipment and cutting-edge technology
- Agrochemical and Synthetic Organic Chemicals facility plant under construction at Dahej III, Gujarat, will be operational by April 2023






ENHANCING POSSIBILITIES. SHAPING TOMORROW.

R&D plays an important role in any Chemical industry. Backed by an experienced and proficient team, Shivalik Rasayan drives its process development, formulation development and research on domestic and international markets. The Company constantly works on its R&D and adopts new technologies to keep up with the latest trends and cater to demand by developing high-quality products. This helps the Company enhance possibilities while it builds on competencies for a progressive tomorrow.

At Shivalik, the R&D team focuses on cost optimisation and the development of non-infringing processes for general APIs. Its analytical research is responsible for leading the method validation, impurity profiling & assessment of its products.




R&D HIGHLIGHTS


- R&D centre approved by DSIR
- World-class set-up for development of Argochemicals, APIs, Intermediates & Process Improvement of Complex Molecules
- Chemical R&D, Analytical R&D for API's & crop protection Argochemicals along with their intermediates
- SLR's R&D is also in a process to optimise some new Argochemicals and its intermediates which will reduce import obligations of India

FINANCIAL PERFORMANCE


REVENUE (₹ in lakhs)




EBIDTA (₹ in lakhs)



PAT (₹ in lakhs)



EPS (₹)





CHAIRMAN'S MESSAGE



Even amid a tumultuous year, we didn't step back. Driven by our commitments, we marched ahead with our heads high. We are proud to contribute to society and our people's well-being. Our down team plays a crucial role in driving the sustainable development of Shivalik Rasayan.



Dear Shareholders,

I'm pleased to present our Company's performance for the fiscal year ended March 31, 2022. As we reflect upon last year, I would like to extend my gratitude to all of you for your unwavering support and faith in us.

The last few years have been difficult to say the least. Covid-19 pandemic affected the production and supply of chemicals in the market. The pandemic impacted the functioning of various industries across the country, including the availability of migrant labourers. The Indian economy has shown a steady recovery post-pandemic and reflected growth at 8.7% in 2021-22. Numerous vaccination drives, resumption of economic activities, Government policies and budgetary allocation along with limited Covid-19 restrictions are further facilitating growth while

raising public morale. The optimism shown by our people has also helped boost the economic revival. Thus, leading India towards becoming one of the fastest-growing major economies. According to research and markets, the Indian healthcare market is expected to reach USD 197 billion by 2025. The Indian Agricultural sector is predicted to reach USD 24 billion by 2025.

At Shivalik Rasayan, we strategically invest in the present to prepare and fight the uncertainties, for a better tomorrow. While consistently focusing on quality enhancement, we also adhere to safe and environment-friendly operations for a sustainable future.

The foundation of our business strategies reflects our ongoing efforts toward making Shivalik Rasayan a responsible corporate entity. We have been consistently

focusing on improving our operations' social, environmental, and economic performance, underpinned by our robust and extensive R&D. We are committed to offer the best solutions while continuously enhancing the landscape of advanced agrochemicals, pharmaceutical intermediates and API.

Our highly qualified and capable scientists help provide the best solutions to our customers. Our associate company, Medicamen Biotech Limited, additionally serves us the benefit of forward integration for our pharmaceutical value chain. This gives us a strong footing to compete in the market's strict IP-driven environment.

Our well-established capacities and far-sightedness help us tap opportunities resulting from various developments in the industry. We are committed to serving top-notch services to the clients. Along with it, we are well-informed of the important changes in the market, as we expand into new regions. These factors, together, enable us to improve our financial standing consistently.

We value and ensure proper care of our highly skilled employees that propel our business' growth. Even amid a tumultuous year, we didn't step back. Driven by our commitments, we marched ahead with our heads high. We are proud to contribute to society and our people's well-being. Our down team plays a crucial role in driving the sustainable development of Shivalik Rasayan. We conduct CSR activities, through which we take an active part in natural resource management, skill and education enhancement and rural development, among others.

In 2021-22, despite the challenges, we maintained a steady pace in progress, and the business grew at a robust 16.27% year-on-year. Even amid various economic hiccups, we recorded our highest-ever revenue, EBITDA and PAT. Revenue increased by 16.27% year-on-year to Rs. 98.67 crores, EBITDA increased by 31.86% year-on-year to Rs. 25.19 crores and PAT increased by 52.70% year-on-year to Rs. 19.35 crores. I'm pleased to report that we made progress toward transforming Shivalik Rasayan

into a stronger, more adaptable, and higher value-creating company throughout the year.

I am also glad to inform that during the current financial year, SRL has filled one Drug Master File (DMF) for **BORTEZOMIB** with **USFDA** and also filled 3 CEP's with **EDQM** for **PIRFENIDONE**, **TEMOZOLOMIDE** and **BUSULFAN**.

Looking ahead, I firmly believe that Shivalik Rasayan Limited is well-positioned to achieve an enhanced leadership position in the market while we make targeted, strategic decisions in line with our disciplined operations. Our world-class infrastructure and persistent emphasis on research and innovation will help us continue 'creating possibilities' for 'shaping future'.

I am grateful to our stakeholders for their unwavering support and inspiration. I want to thank our suppliers, our bankers and partners for their constant cooperation. All of this progress wouldn't have been possible without the guidance of our Board. I am extremely proud of the work and the dedication of our highly skilled team. This gives us more confidence to march ahead, uninterruptedly serving our commitments with excellence.

Best Wishes,
Rahul Bishnoi,
Chairman

“Despite crosswinds and challenges, our actionable plan led by strong team efforts enabled us to stand tall. With best-in-class facilities, innovation, research and infrastructure, we facilitate the development of new products which further helps us gain product distinction in the market.”

Dr. Vimal Kumar Shrawat
Managing Director





BOARD OF DIRECTORS

RAHUL BISHNOI
Chairman

SURESH KUMAR SINGH
Vice Chairman

Corporate Social Responsibility
Committee - Chairperson

DR. VIMAL KUMAR SHRAWAT
Managing Director

ASHWANI KUMAR SHARMA
Executive Director

Corporate Social Responsibility
Committee - Member

DR. AKSHAY KANT CHATURVEDI
Executive Director

HARISH PANDE
Independent Director

Audit Committee - Chairperson
Nomination and Remuneration
Committee - Chairperson
Stakeholders Relationship
Committee - Chairperson
Risk Management
Committee - Chairperson
Corporate Social Responsibility
Committee - Member

KAILASH GUPTA
Independent Director

ARUN KUMAR
Independent Director

Audit Committee - Member
Nomination and Remuneration
Committee - Member
Stakeholders Relationship
Committee - Member
Risk Management
Committee - Member
Corporate Social Responsibility
Committee - Member

SANGEETA BISHNOI
Independent Director

SUMITA DWIVEDI
Independent Director

RAVI KUMAR BANSAL
Independent Director

SANJAY BANSAL
Non-Executive Director

Audit Committee - Member
Nomination and Remuneration
Committee - Member
Stakeholders Relationship
Committee - Member
Risk Management
Committee - Member